From physical pharmacy to clinical pharmacology.
Research works on molecular interactions in solutions were carried out at School of Pharmacy, the University of Wisconsin under the direction of Prof. T. Higuchi and at Faculty of Pharmaceutical Sciences, Kyoto University under the direction of Prof. H. Sezaki. Studies on permeation of drugs through polymer membranes were carried out at Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada and at Pharmaceutical Chemistry Research Laboratories at Food and Drug Directorate, Department of Health and Welfare, Canada. Studies on modification of delivery patterns by means of pharmaceutical approaches were carried out at Faculty of Pharmaceutical Sciences, Hokkaido University. Topics related to modification of drug delivery patterns include employment of amorphous forms such as ground mixture with micro-crystalline cellulose and coprecipitate with polyvinylpyrrolidone, use of biodegradable polymers such as polylactic acid and polycarbonates, gel-forming materials such as konjac, agar and hydroxypropylcellulose, and physicochemical systems such as complexation. Works related to drug delivery and disposition of drugs in humans were carried out at Department of Pharmacy, Kumamoto University Hospital. Topics related to drug delivery in humans include injections containing anticancer drugs for intra-arterial administration, lidocaine gels for dermal anesthesia, glucagon solution for nasal administration. Topics related to disposition of drugs in humans include clinical pharmacokinetic studies in infants and elderly and medical uses of adsorbents.
Nakano
Masahiro
M
Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan. nakano_mshr@yahoo.co.jp
D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001673:Biodegradation, Environmental; D001682:Biological Availability; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D065731:Cytochrome P-450 CYP2C19; D016503:Drug Delivery Systems; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics; D010597:Pharmacogenetics; D010599:Pharmacokinetics; D010601:Pharmacology, Clinical; D011076:Polycarboxylate Cement; D011108:Polymers; D011110:Polymorphism, Genetic; D012996:Solutions; D013535:Suspensions
D011076:Polycarboxylate Cement; D011108:Polymers; D012996:Solutions; D013535:Suspensions; C005506:polycarbonate; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19